* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA
* PUMA WILL RECEIVE AN UPFRONT PAYMENT AS WELL AS POTENTIAL REGULATORY AND COMMERCIAL MILESTONE PAYMENTS TOTALING UP TO $34.5 MILLION
* DEAL FOR PINT PHARMA TO COMMERCIALIZE NERLYNX IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, MEXICO AND REST OF LATIN AMERICA
* PINT PHARMA WILL BE RESPONSIBLE FOR COMMERCIALIZING NERLYNX IN LATIN AMERICA Source text for Eikon: Further company coverage: